Diversify Advisory Services LLC Makes New Investment in Repligen Corporation $RGEN

Posted by Stanley Muller on Aug 19th, 2026

Diversify Advisory Services LLC bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) during the 2nd quarter, Holdings Channel.com reports. The fund bought 18,594 shares of the biotechnology company’s stock, valued at approximately $2,437,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. M&T Bank Corp bought a new position in shares of Repligen in the 4th quarter worth $29,819,000. Avidity Partners Management LP boosted its position in Repligen by 54.7% during the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company’s stock valued at $9,166,000 after purchasing an additional 27,500 shares in the last quarter. Swedbank AB bought a new stake in Repligen during the fourth quarter valued at about $4,146,000. Conestoga Capital Advisors LLC grew its stake in Repligen by 10.6% in the fourth quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company’s stock valued at $173,360,000 after purchasing an additional 101,062 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in Repligen in the fourth quarter valued at about $20,253,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Jefferies Financial Group reissued a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. HSBC cut their price objective on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Wolfe Research assumed coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective for the company. Barclays lifted their price target on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Repligen has an average rating of “Buy” and an average target price of $166.43.

View Our Latest Analysis on RGEN

Repligen Price Performance

Shares of RGEN stock opened at $166.15 on Wednesday. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The firm has a market capitalization of $9.38 billion, a price-to-earnings ratio of 227.60, a PEG ratio of 3.04 and a beta of 1.03. The stock’s 50-day simple moving average is $144.29 and its 200-day simple moving average is $131.18.

Repligen (NASDAQ:RGEN – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. Repligen’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insider Activity

In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Repligen Company Profile

(Free Report)

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.